



03-20-00

IFW

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. : EV 841058245 US

Serial No. : 10/777,488

Applicant(s) : Adnan M.M. Mjalli et al.

Filing Date : February 12, 2004

Title: : Substituted Azole Derivatives As
Therapeutic Agents

Examiner : Laura Stockton

Group Art Unit : 1626

Type of Document(s) : Express Mail Certificate;
Transmittal Form;
Supplemental Information Disclosure Statement;
PTO/SB/08A Forms; and
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Mail Stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Christine Heerschap (signature)
Christine Heerschap

Date Mailed: 3/17/06

EV 841058245 US

PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/777,488
	Filing Date	February 12, 2004
	First Named Inventor	Adnan M.M. Mjalli et al.
	Art Unit	1626
	Examiner Name	Laura Stockton
Total Number of Pages in This Submission	Attorney Docket Number	TTP 2002-08

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Express Mail Certificate; PTO/SB/08a Forms; and Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm			
Signature			
Printed Name	Samuel B. Rollins		
Date	March 17, 2006	Reg. No.	52,180

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. 841058245 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Adnan M.M. Mjalli et al.
Ser. No. : 10/777,488
Filing Date : February 2, 2004
Title : Substituted Azole Derivatives as Therapeutic Agents
Examiner : Laura Stockton
Art Unit : 1626
Atty. Docket : TTP 2002-08

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08a.

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

I. COPIES

- ☐ 1. This application was filed before June 30, 2003. Accordingly, submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- ☒ 2. This application was filed on or after June 30, 2003. Accordingly, copies of cited U.S. patents and patent applications are not included. Copies of foreign patent documents and non-patent literature are included.
- ☐ 3. Under 37 C.F.R. § 1.98 (d) copies of the references listed on the attached PTO/SB08a forms are not required to be provided to the Patent and Trademark Office because they were previously submitted to or cited by the Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35 U.S.C. § 120.

II. CONCISE EXPLANATION OF RELEVANCE

- ☒ 1. DOCUMENTS IN THE ENGLISH LANGUAGE
The patents, publications, or other information listed on the attached PTO/SB/08a are in the English language and do not require a statement of relevancy.
- ☒ 2. DOCUMENTS NOT IN THE ENGLISH LANGUAGE
- ☒ a. CONCISE EXPLANATION
A concise explanation of the relevance of patents, publications, or other information listed that is not in the English language is as follows:
- 1) TR-755 (JP 63-276054) is in Japanese. The relevant portion of this reference includes pages 482-486 where structures of imidazoles 1-60 are disclosed.
- 2) TR-756 (WO 1994/17059) is in Japanese. The relevant portion of this reference includes pages 52-54 where Tables 1, 2, and 3 disclose a series of substituted imidazoles.
- 3) TR-760 (WO 2000/27826) is in German. The relevant portion of this reference includes the examples on pages 26-78 where various substituted amino pyrimidines are disclosed.
- 4) TR-339 (WO 1994/008982) is in Japanese. The relevant portion of this reference includes the compounds in Table 1 on pages 15-22 where various substituted azole derivatives are disclosed.
- ☐ b. ENGLISH LANGUAGE SEARCH REPORT
An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. MPEP 609.04(a)(III).
- ☒ c. OTHER
The following additional information is provided for the Examiner's consideration.
English language abstracts are provided for the following non-English references:
TR-337, -338, -339, -345, -414, -417, -418, -754, -755, -756, and -760.

Machine language translations are provided for the following references:

TR-337, -338, -414, -417, -418, and -754.

Related applications in English:

Reference TR-666 (EP 1 553 091) is a European application filed on the same day as the foreign language reference TR-345 (WO 2004/089918) and claims priority to the same two Japanese patent applications as TR-345.

III. FEES

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ c. Please debit Deposit Account No. 50-3216 in the amount of \$_____ in payment of the fee under 37 C.F.R. § 1.17(p). Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the

Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Please debit Deposit Account No. 50-3216 in the amount of \$ _____ in payment of the petition fee under 37 C.F.R. § 1.17(p). Two duplicate copies of this paper are attached.


- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97 (e)(2).

IV. PATENT TERM ADJUSTMENT

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: March 17, 2006


Samuel B. Rollins
Registration No. 52,180

TransTech Pharma, Inc.
4170 Mendenhall Oaks Pkwy, Suite 110
High Point, NC 27265
Phone: (336) 841-0300
Fax: (336) 841-0310

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/777,488
Filing Date	February 12, 2004
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	TR-333	US- 2005-0014805	01/20/2005	Zhang et al.	
	TR-350	US- 2004-0186151	09/23/2004	Mjalli et al.	
	TR-351	US- 2004-0192743	09/30/2004	Mjalli et al.	
	TR-352	US- 2004-0082542	04/29/2004	Mjalli et al.	
	TR-734	US- 5,106,732	04/21/1992	Kondo et al.	
	TR-735	US- 5,510,362	04/23/1996	Matassa et al.	
	TR-736	US- 5,616,601	04/01/1997	Khanna et al.	
	TR-737	US- 5,700,816	12/23/1997	Isakson et al.	
	TR-738	US- 5,753,687	05/19/1998	Mjalli et al.	
	TR-739	US- 5,840,721	11/24/1998	Mjalli et al.	
	TR-740	US- 5,958,957	09/28/1999	Andersen et al.	
	TR-741	US- 5,972,986	10/26/1999	Seibert et al.	
	TR-742	US- 5,990,148	11/23/1999	Isakson et al.	
	TR-743	US- 6,136,839	10/24/2000	Isakson et al.	
	TR-744	US- 6,159,944	12/12/2000	McDonald et al.	
	TR-745	US- 6,265,426	07/24/2001	Alanine et al.	
	TR-746	US- 6,358,634	03/19/2002	Igarashi et al.	
	TR-747	US- 6,589,953	07/08/2003	Perez et al.	
	TR-748	US- 6,627,647	09/30/2003	Betageri	
	TR-749	US- 2003-0220372	11/27/2003	Hirano et al.	
	TR-750	US- 2004-0167187	08/26/2004	Saunders et al.	
	TR-751	US- 2004-0176395	09/09/2004	Flynn et al.	
	TR-752	US- 2004-0180906	09/16/2004	Flynn et al.	
	TR-753	US- 2005-0272778	12/08/2005	Combs et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	TR-414	JP 09040651	02/10/1997	Yasushi et al.		✓
	TR-417	JP 2003313170	11/06/2003	Takahashi et al.		✓
	TR-418	JP 2003313172	11/06/2003	Takahashi et al.		✓
	TR-754	JP 05261293	10/12/1993	Benazzi et al.		✓
	TR-755	JP 63276054	11/14/1988	Shigeo et al.		
	TR-756	WO 199417059	08/04/1994	Miyazawa et al.		
	TR-757	WO 199641626	12/27/1996	Isakson et al.		
	TR-758	WO 199816227	4/23/1998	Seibert et al.		
	TR-759	WO 199851673	11/19/1998	Earnshaw et al.		
	TR-760	WO 200027826	05/18/2000	Lehmann-Lintz et al.		
	TR-761	WO 2004069394	08/19/2004	Sames et al.		
	TR-762	WO 2004094395	11/04/2004	Chakravarty et al.		
	TR-764	CA 2158529	03/27/1996	Marten et al.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/777,488
Filing Date	February 12, 2004
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	TR-47	TAYLOR SD, "Inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Current Topics in Medicinal Chemistry, 3:759-782 (2003)	
	TR-48	TAO J, "Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo." The Journal of Biological Chemistry, 276:29520-29525 (2001)	
	TR-49	DADKE S, "Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains." Biochemical Journal, 364:377-383 (2002)	
	TR-51	BLANCHETOT C, "Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases." The Journal of Biological Chemistry, 277:47263-47269 (2002)	
	TR-52	HAASE H, "Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling." Experimental Cell Research, 291:289-298 (2003)	
	TR-53	LILJEBRIS C, "Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity." Journal of Medicinal Chemistry, 45:1785-1798 (2002)	
	TR-54	FRIMURER TM, "Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities." Biophysical Journal, 84:2273-2281 (2003)	
	TR-55	TJERNBERG A, "Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)" Bioorganic & Medicinal Chemistry Letters, 14:891-895 (2004)	
	TR-56	LARSEN SD, "Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity." Bioorganic & Medicinal Chemistry Letters, 13:971-975 (2003)	
	TR-57	SALMEEN A, "Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B." Molecular Cell, 6:1401-1412 (2000)	
	TR-58	UMEZAWA K, "Molecular design and biological activities of protein-tyrosine phosphatase inhibitors." Pharmacology & Therapeutics, 99:15-24 (2003)	
	TR-346	COCCO et al., "L-Acylaminoimidazoles Synthesis and Antimicrobial Activity", Farmaco, vol. 47, no. 2, pages 229-238, (1992)	
	TR-347	International Search Report for PCT application PCT/US2005/004590 mailed September 8, 2005.	
	TR-348	LAUFER et al., "Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position", vol. 45, pages 4695-4705, (2002)	
	TR-349	LIPSHUTZ et al., "Metalation Studies of Trisubstituted Oxazoles", Journal of Organic Chemistry, vol. 46, pages 1410-1413, (1981)	
	TR-350-A	MEANWELL et al., "Nonprostanoid prostacyclin mimetics. 2. 4, 5-Diphenyloxazole derivatives", Journal of Medicinal Chemistry, vol. 35, no. 19, pages 3483-3497, (1992)	
	TR-763	Combs et al., "Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics" Journal of Medicinal Chemistry, Vol. 48, pp. 6544-6548 (2005).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

<i>Application Number</i>	10/777,488
<i>Filing Date</i>	February 12, 2004
<i>First Named Inventor</i>	Adnan M.M. Mjalli
<i>Art Unit</i>	1626
<i>Examiner Name</i>	Laura Stockton
<i>Attorney Docket Number</i>	TTP 2002-08

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	TR-334	EP 1 227 084	07/31/2002	Leger et al.		
	TR-335	EP 1 253 142	10/30/2002	Takemoto et al.		
	TR-336	EP 1 452 530	09/01/2004	Inaba et al.		
	TR-337	JP 2002-114768	04/16/2002	Takeshi et al.		✓
	TR-338	JP 2003-231679	08/19/2003	Atsunori et al.		✓
	TR-339	WO 1994-008982	04/28/1994	Kumita et al.		
	TR-340	WO 2000-071120	11/30/2000	Heerding et al.		
	TR-341	WO 2003-075921	09/18/2003	Mjalli et al.		
	TR-342	WO 2003-093263	11/13/2003	Maynard et al.		
	TR-343	WO 2004-013141	02/12/2004	Luke et al.		
	TR-344	WO 2004-063169	07/29/2004	Urano et al.		
	TR-345	WO 2004-089918	10/21/2004	Ikemoto et al.		
	TR-766	EP 1 553 091	07/13/2005	Ikemoto et al.		

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kindred Codes of USPTO Patent Documents at www.uspto.gov or MPEP § 01.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Standard ST. 16, if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. ⁶ Applicants on the amount of time to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.